Arch Therapeutics is positioned as a life science medical device company. The company centers its endeavors on developing products by utilizing a novel approach to stop bleeding and control leaking during surgical procedures and trauma care. Leading product candidate, AC5 Surgical Hemostatic Device, is a biocompatible synthetic peptide made up of naturally occurring amino acids to achieve hemostasis in minimally invasive and open surgical procedures. Founded in 2006, the company is headquartered in Wellesley, Massachusetts. For more information, visit the company’s website at www.archtherapeutics.com.